Overview

Efficacy, Safety and Pharmacokinetics of Topical Timolol in Infants With Infantile Hemangioma (IH)

Status:
Completed
Trial end date:
2020-04-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and efficacy of Timolol 0.25% and 0.5% doses.
Phase:
Phase 2
Details
Lead Sponsor:
Chiara Melloni
Kanecia Zimmerman, MD MPH
Collaborators:
National Institutes of Health (NIH)
The Emmes Company, LLC
The EMMES Corporation
Treatments:
Maleic acid
Pharmaceutical Solutions
Timolol